Calidi Biotherapeutics (NYSE:CLDI) Trading Up 5.6% – Still a Buy?

Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) traded up 5.6% during mid-day trading on Friday . The company traded as high as $0.25 and last traded at $0.25. 551,055 shares traded hands during trading, a decline of 45% from the average session volume of 1,009,937 shares. The stock had previously closed at $0.23.

Calidi Biotherapeutics Trading Up 5.6%

The stock’s fifty day simple moving average is $0.36 and its 200-day simple moving average is $0.71.

Institutional Trading of Calidi Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in Calidi Biotherapeutics in the 4th quarter valued at approximately $38,000. RS Crum Inc. bought a new stake in shares of Calidi Biotherapeutics in the fourth quarter valued at approximately $47,000. Virtu Financial LLC bought a new stake in shares of Calidi Biotherapeutics in the fourth quarter valued at approximately $84,000. HighTower Advisors LLC acquired a new stake in shares of Calidi Biotherapeutics in the fourth quarter worth $118,000. Finally, Belpointe Asset Management LLC acquired a new stake in shares of Calidi Biotherapeutics in the first quarter worth $141,000. Institutional investors own 12.53% of the company’s stock.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.